Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 3:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Tazobactam Clear all
Terminated Phase 4 Interventional Results available

BL Infusion Trial:Beta-lactam Continuous Versus Intermittent Infusion and Associated Bacterial Resistance and Therapy Outcomes in Critically Ill Patients With Severe Pneumonia

NCT05102162
View directory record Official record
Conditions
Pneumonia
Interventions
Cefepime, Meropenem, or Piperacillin/Tazobactam
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 100 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 11, 2023 · Synced Sep 23, 2026, 3:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study Designed to Study the Effects of Two Different Doses of CXA-101/Tazobactam, a Low Dose and a High Dose, on the QT/QTc Intervals in Healthy Subjects

NCT02508753
View directory record Official record
Conditions
Healthy
Interventions
CXA-101/tazobactam, Moxifloxacin, placebo
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 45 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Jan 25, 2017 · Synced Sep 23, 2026, 3:10 PM EDT
Recruiting Phase 4 Interventional

The Vancomycin Piperacillin/Tazobactam (VPT) Patient Safety Trial (VPS)

NCT07556107
View directory record Official record
Conditions
Infection, Acute Kidney Injury, Sepsis
Interventions
Piperacillin + Tazobactam, meropenem
Drug
Lead sponsor
Bassett Healthcare
Other
Eligibility
18 Years and older
Enrollment
852 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
3
States / cities
Cooperstown, New York • Winston-Salem, North Carolina • Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 23, 2026, 3:10 PM EDT
Active, not recruiting Phase 2 Interventional

RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD)

NCT04514653
View directory record Official record
Conditions
Neovascular Age-Related Macular Degeneration (nAMD)
Interventions
Ranibizumab, ABBV-RGX-314 Dose 1, ABBV-RGX-314 Dose 2, ABBV-RGX-314 Dose 3, Local Steroid, Topical Steroid, ABBV-RGX-314 Dose 4
Biological · Genetic · Drug
Lead sponsor
AbbVie
Industry
Eligibility
50 Years to 89 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
18
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Sep 23, 2026, 3:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Tissue Penetration of Ceftolozane/Tazobactam in Diabetic Patients With Lower Limb Infections

NCT02620774
View directory record Official record
Conditions
Diabetes, Wound Infection, Healthy Volunteers
Interventions
Ceftolozane/tazobactam, Microdialysis Catheter Insertion
Drug · Procedure
Lead sponsor
Hartford Hospital
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 14, 2019 · Synced Sep 23, 2026, 3:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single-dose Study to Investigate the Pharmacokinetics of Intravenous FEP-TAZ in Patients With Renal Impairment

NCT02709382
View directory record Official record
Conditions
Renal Impairment
Interventions
Cefepime and Tazobactam combination
Drug
Lead sponsor
Wockhardt
Industry
Eligibility
18 Years to 80 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 25, 2016 · Synced Sep 23, 2026, 3:10 PM EDT
Terminated Not applicable Interventional Results available

Operative vs Non-Operative Management of Acute Appendicitis and Acute Cholecystitis in COVID-19 Positive Patients

NCT04748120
View directory record Official record
Conditions
Covid19, Appendicitis, Cholecystitis, Acute, Cholecystitis; Gallstone, Cholecystitis
Interventions
Operative management, Non-operative management
Procedure
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 13, 2022 · Synced Sep 23, 2026, 3:10 PM EDT
Completed Phase 3 Interventional Results available

Efficacy/Safety of Meropenem-Vaborbactam Compared to Piperacillin-Tazobactam in Adults With cUTI and AP

NCT02166476
View directory record Official record
Conditions
Urinary Tract Infection Complicated, Acute Pyelonephritis
Interventions
Meropenem-Vaborbactam, Piperacillin-Tazobactam, Levofloxacin, Saline
Drug
Lead sponsor
Melinta Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
8
States / cities
Mobile, Alabama • San Diego, California • Denver, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2018 · Synced Sep 23, 2026, 3:10 PM EDT
Completed Phase 1 Interventional Results available

Pharmacokinetics and Safety of Piperacillin-tazobactam in Neonates

NCT00873327
View directory record Official record
Conditions
Sepsis
Interventions
piperacillin-tazobactam
Drug
Lead sponsor
Phillip Brian Smith
Other
Eligibility
Up to 60 Days
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
4
States / cities
Indianapolis, Indiana • Wichita, Kansas • Kansas City, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2018 · Synced Sep 23, 2026, 3:10 PM EDT
Terminated Phase 4 Interventional Results available

Pharmacokinetics of Ceftolozane/Tazobactam in Patients With Burns

NCT03002506
View directory record Official record
Conditions
Burns, Pharmacokinetics
Interventions
Ceftolozane/tazobactam
Drug
Lead sponsor
Texas Tech University Health Sciences Center
Other
Eligibility
18 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Mar 1, 2021 · Synced Sep 23, 2026, 3:10 PM EDT
Not yet recruiting Phase 2 Interventional

Cefotetan Therapy for Escherichia Coli Infections

NCT07318584
View directory record Official record
Conditions
E Coli Infection, ESBL Producing E.Coli
Interventions
Cefotetan, Carbapenems, Beta Lactam Antibiotics
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 5, 2026 · Synced Sep 23, 2026, 3:10 PM EDT
Completed Phase 2 Interventional Results available

MK-7625A Plus Metronidazole Versus Meropenem in Pediatric Participants With Complicated Intra-Abdominal Infection (cIAI) (MK-7625A-035)

NCT03217136
View directory record Official record
Conditions
Complicated Intra-Abdominal Infection
Interventions
Ceftolozane/Tazobactam, Metronidazole, Meropenem, Placebo for Metronidazole
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
7 Days to 17 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
9
States / cities
Los Angeles, California • Orange, California • San Diego, California + 6 more
Source: ClinicalTrials.gov public record
Updated May 5, 2023 · Synced Sep 23, 2026, 3:10 PM EDT
Terminated Phase 3 Interventional Results available

Study of Intravenous Ceftolozane/Tazobactam Compared to Piperacillin/Tazobactam in Ventilator-Associated Pneumonia

NCT01853982
View directory record Official record
Conditions
Ventilator-Associated Pneumonia (VAP)
Interventions
Ceftolozane/Tazobactam, Piperacillin/Tazobactam
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
11
States / cities
Jacksonville, Florida • Chicago, Illinois • Baltimore, Maryland + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Sep 23, 2026, 3:10 PM EDT
Active, not recruiting Phase 2 Interventional

Choosing the Best Antibiotic to Protect Friendly Gut Bacteria During the Course of Stem Cell Transplant

NCT03078010
View directory record Official record
Conditions
Intestinal Microbiome, Febrile Neutropenia
Interventions
Piperacillin-tazobactam, cefepime
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
347 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
2
States / cities
Hackensack, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Sep 23, 2026, 3:10 PM EDT
Completed No phase listed Observational

Risk Factors for Piperacillin/Tazobactam Resistance in Extended-Spectrum Beta-Lactamase (ESBL) Producing Organisms

NCT00573521
View directory record Official record
Conditions
Enterobacteriaceae Infections
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 11, 2018 · Synced Sep 23, 2026, 3:10 PM EDT
Completed No phase listed Observational

Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care

NCT01431326
View directory record Official record
Conditions
Adenovirus, Anesthesia, Anxiety, Anxiolysis, Autism, Autistic Disorder, Bacterial Meningitis, Bacterial Septicemia, Benzodiazepine, Bipolar Disorder, Bone and Joint Infections, Central Nervous System Infections, Convulsions, Cytomegalovirus Retinitis, Early-onset Schizophrenia Spectrum Disorders, Epilepsy, General Anesthesia, Gynecologic Infections, Herpes Simplex Virus, Infantile Hemangioma, Infection, Inflammation, Inflammatory Conditions, Intra-abdominal Infections, Lower Respiratory Tract Infections, Migraines, Pain, Pneumonia, Schizophrenia, Sedation, Seizures, Skeletal Muscle Spasms, Skin and Skin-structure Infections, Treatment-resistant Schizophrenia, Urinary Tract Infections, Withdrawal, Sepsis, Gram-negative Infection, Bradycardia, Cardiac Arrest, Cardiac Arrhythmia, Staphylococcal Infections, Nosocomial Pneumonia, Neuromuscular Blockade, Methicillin Resistant Staphylococcus Aureus, Endocarditis, Neutropenia, Headache, Fibrinolytic Bleeding, Pulmonary Arterial Hypertension, CMV Retinitis, Hypertension, Chronic Kidney Diseases, Hyperaldosteronism, Hypokalemia, Heart Failure, Hemophilia, Heavy Menstrual Bleeding, Insomnia
Interventions
The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
Drug
Lead sponsor
Daniel Benjamin
Other
Eligibility
Up to 21 Years
Enrollment
3,520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
43
States / cities
Anchorage, Alaska • Little Rock, Arkansas • La Jolla, California + 37 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2023 · Synced Sep 23, 2026, 3:10 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

SYN-004 Safety and Tolerability in Allo-HCT Subjects

NCT04692181
View directory record Official record
Conditions
Acute Graft-Versus-Host Reaction Following Bone Marrow Transplant, Prevention of CDI in Adult Patients Being Treated With IV Beta-lactam Antibiotics
Interventions
SYN-004, Ribaxamase or Placebo
Biological
Lead sponsor
Theriva Biologics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Sep 23, 2026, 3:10 PM EDT
Terminated Phase 2 Interventional Results available

eXtended Antibiotic Prophylaxis for Intermediate- and High-risk Glands After Pancreatoduodenectomy to Reduce CR-POPF

NCT05753735
View directory record Official record
Conditions
Pancreatic Fistula
Interventions
Piperacillin/Tazobactam, Amoxicillin/ Clavulanic acid
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 23, 2024 · Synced Sep 23, 2026, 3:10 PM EDT
Completed Phase 4 Interventional Results available

Optimal Care of Complicated Appendicitis

NCT03159754
View directory record Official record
Conditions
Appendicitis, Perforated Appendicitis, Ruptured Appendicitis, Complicated Appendicitis
Interventions
Early Appendectomy, Interval Appendectomy, Antibiotics
Procedure · Drug
Lead sponsor
University of Michigan
Other
Eligibility
5 Years to 17 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 27, 2023 · Synced Sep 23, 2026, 3:10 PM EDT
Completed Phase 2 Interventional Results available

MK-7625A Versus Meropenem in Pediatric Participants With Complicated Urinary Tract Infection (cUTI) (MK-7625A-034)

NCT03230838
View directory record Official record
Conditions
Complicated Urinary Tract Infection, Pyelonephritis
Interventions
Ceftolozane/Tazobactam, Meropenem
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
7 Days to 17 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
9
States / cities
Los Angeles, California • Orange, California • San Diego, California + 6 more
Source: ClinicalTrials.gov public record
Updated May 5, 2023 · Synced Sep 23, 2026, 3:10 PM EDT
Terminated Phase 3 Interventional

Pivotal Study in VAP Suspected or Confirmed to be Due to Pseudomonas Aeruginosa

NCT03409679
View directory record Official record
Conditions
Pneumonia
Interventions
Murepavadin, Two anti-pseudomonal antibiotics
Drug
Lead sponsor
Polyphor Ltd.
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Chicago, Illinois • Springfield, Missouri • Greensboro, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 27, 2019 · Synced Sep 23, 2026, 3:10 PM EDT
Completed Phase 2 Interventional Results available

Comparative Study To Determine The Efficacy, Safety, And Tolerability Of Ceftolozane-Tazobactam

NCT03485950
View directory record Official record
Conditions
Other Infectious Diseases
Interventions
Cefepime, Ceftolozane, Laboratory Biomarker Analysis, Meropenem, Piperacillin-Tazobactam, Tazobactam
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 14, 2022 · Synced Sep 23, 2026, 3:10 PM EDT
Completed Not applicable Interventional

Standard vs. Biofilm Susceptibility Testing in Cystic Fibrosis (CF)

NCT00153634
View directory record Official record
Conditions
Cystic Fibrosis, Chronic Bronchitis
Interventions
IV amikacin, PO azithromycin, IV ceftazidime, PO ciprofloxacin, IV meropenem, IV piperacillin-tazobactam, IV ticarcillin-clavulanate, IV tobramycin
Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
14 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
8
States / cities
Iowa City, Iowa • St Louis, Missouri • Cincinnati, Ohio + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2008 · Synced Sep 23, 2026, 3:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

To Investigate the Multiple Dose Safety, Tolerability and Pharmacokinetics of WCK 4282 (FEP-TAZ)

NCT03622008
View directory record Official record
Conditions
Antibiotics Causing Adverse Effects in Therapeutic Use
Interventions
FEP-TAZ 4 g, Placebo
Drug · Other
Lead sponsor
Wockhardt
Industry
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 9, 2018 · Synced Sep 23, 2026, 3:10 PM EDT